Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI). - Wikidata - awgldk - TriplyDB

Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI).

Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI).

http://www.wikidata.org/entity/Q33917702

about

Brain fuel metabolism, aging, and Alzheimer's disease Toward precision medicine in Alzheimer's disease The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015 Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers Vascular contributions to cognitive impairment and dementia including Alzheimer's disease Brain imaging in Alzheimer disease The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception Ushering in the study and treatment of preclinical Alzheimer disease Neuroimaging biomarkers of neurodegenerative diseases and dementia Examining the relationship between head trauma and neurodegenerative disease: A review of epidemiology, pathology and neuroimaging techniques Genetic analysis of quantitative phenotypes in AD and MCI: imaging, cognition and biomarkers Pioglitazone improves reversal learning and exerts mixed cerebrovascular effects in a mouse model of Alzheimer's disease with combined amyloid-β and cerebrovascular pathology Genetic variants in Alzheimer disease - molecular and brain network approaches Imago Mundi, Imago AD, Imago ADNI The Alzheimer's disease neuroimaging initiative: progress report and future plans Comparing 3 T and 1.5 T MRI for tracking Alzheimer's disease progression with tensor-based morphometry.2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.Insulin Resistance as a Link between Amyloid-Beta and Tau Pathologies in Alzheimer's Disease.Neuroimaging in the clinical diagnosis of dementia: observations from a memory disorders clinic.Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease.Voxel-wise correlations between cognition and cerebral blood flow using arterial spin-labeled perfusion MRI in patients with Alzheimer's disease: a cross-sectional study [Neuroimaging in Alzheimer's disease: a synthesis and a contribution to the understanding of physiopathological mechanisms].Mapping Alzheimer's disease progression in 1309 MRI scans: power estimates for different inter-scan intervals.Alzheimer's prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible.Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: findings from the Alzheimer's Disease Neuroimaging Initiative Smoking and increased Alzheimer's disease risk: a review of potential mechanisms Higher serum total cholesterol levels in late middle age are associated with glucose hypometabolism in brain regions affected by Alzheimer's disease and normal aging.Can Functional Magnetic Resonance Imaging Improve Success Rates in CNS Drug Discovery?Integrating ADNI results into Alzheimer's disease drug development programs.Functional connectivity density mapping.Multi-Channel neurodegenerative pattern analysis and its application in Alzheimer's disease characterization.Cognition, glucose metabolism and amyloid burden in Alzheimer's disease.The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core.The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.Sex and age differences in atrophic rates: an ADNI study with n=1368 MRI scans Imaging approaches for dementia.Brain imaging in the study of Alzheimer's disease Hypometabolism in Alzheimer-affected brain regions in cognitively healthy Latino individuals carrying the apolipoprotein E epsilon4 allele Assessing the reliability to detect cerebral hypometabolism in probable Alzheimer's disease and amnestic mild cognitive impairment.Vascular and metabolic dysfunction in Alzheimer's disease: a review.

P2860

Q24625859-A49C3221-47AA-49DD-A2DF-831B341E624B Q26748939-8F819BEE-F335-49FC-BF4A-203479DB0653 Q26801654-9BB45B9B-2456-43CC-8D55-7A418106283C Q26825442-AB5DE73B-3387-4500-8853-2BEEC72BF143 Q26852882-8D931EEF-1003-4763-B70C-44817561FA7A Q26996299-E915251F-49B7-4033-B30B-7626930DC1AC Q27006831-F9C05285-5AC0-4C9E-98CE-3EFA976E01C9 Q27014791-717053B2-F339-449D-808E-DB0E763A5BAB Q27691820-2FA5CE83-7214-4F76-ADF2-345EF5D0B8E1 Q28395854-3DBF15E0-8D72-4732-98A3-E32B1C56302D Q28542010-D8109A9C-ADA1-4A1C-969C-0CE78B6F3F51 Q28594423-92EDCF91-35CC-4572-966F-673C9C73C17A Q28596011-64301185-5819-4204-B96F-3CBA7B94F543 Q28650395-8A38F66A-A64A-42B4-812E-069379690DC9 Q28749585-B89E9FF4-CDDB-49A8-8F25-5B4274F78F6A Q30476040-61236A28-46AD-4B82-B772-E2701BE295BB Q30971403-D3181D2F-9F3F-46F7-BC49-CC85468D0911 Q33628048-362DFD81-97E8-4F4D-9068-44AD1892D46F Q33644896-61C602DC-7083-491E-A11E-FA8230965086 Q33651118-31AB7AB5-28FB-48D4-A6E9-D55EC147AAAF Q33691776-F9EC79B7-FB21-432D-B933-8CE18E3E29D9 Q33720033-099C6091-84F1-4E52-AE75-E9C6E10CC209 Q33759240-8D8DD796-EF92-4840-9D90-D34C18697150 Q33773031-4F3182D3-4827-499E-B3CB-57E97EE1F170 Q33798435-E1D52312-4EFF-4646-AB1E-A15A70529EBF Q33902721-F5E81AC0-76AA-4938-B2D3-06C3195B073D Q33925913-CCA0E02B-AFD1-4CB8-88BF-1E57E25D5BC8 Q33963735-67BEB619-7332-4671-82CF-26611A4C19D6 Q33987409-070CD423-0EBB-4194-BFC3-BDF93D03F4D9 Q34006786-AD741917-FCEB-46C6-A800-4860D6390F07 Q34053888-7B6FF2A2-956E-4AAF-AF3A-E52879CBD20E Q34061233-6D3BD6C4-50D0-4366-850B-E00832631F91 Q34061794-4034CE5A-E8CE-475C-85E2-56C43CD95482 Q34065449-73732677-2A89-46AB-BE3C-EF733311CDDF Q34081087-47D57972-1D93-4215-9364-4DFF933C31ED Q34089121-5726ACA4-A4FC-4F13-9AE8-1AF27B77BE25 Q34102331-CF7DECB8-6EE3-44E0-85F8-89D79551BEBF Q34145373-3687B403-9BC2-4627-AC5A-99E7ED033643 Q34187712-EF050961-5D84-4F54-85A5-2ACB4C821209 Q34193337-B5DFDA6E-C8A3-4757-92FD-AF035FC84E11

P2860

Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI).

http://www.wikidata.org/entity/Q33917702

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

name

Categorical and correlational ...... euroimaging Initiative (ADNI).

@ast

Categorical and correlational ...... euroimaging Initiative (ADNI).

@en

type

label

Categorical and correlational ...... euroimaging Initiative (ADNI).

@ast

Categorical and correlational ...... euroimaging Initiative (ADNI).

@en

prefLabel

Categorical and correlational ...... euroimaging Initiative (ADNI).

@ast

Categorical and correlational ...... euroimaging Initiative (ADNI).

@en

P1433

Q33917702-A8AEF7C8-F07C-4636-9925-5124543B8586

P1476

Q33917702-A60FFFF4-DD3E-4117-845A-D9CE22D51E49

P2093

Q33917702-0410A478-3295-41B6-9465-F76D7DEB0C43

Q33917702-061D4A65-DBFA-41A7-B89E-9D77A38E8649

Q33917702-0E9281B7-A50F-48E3-BAAD-ABF2EF56AD72

Q33917702-1E219012-3FAC-4167-A745-69EBE8E9DF33

Q33917702-696CD0DA-9A21-44AE-958A-2699E0663E2D

Q33917702-6CB351A4-7192-4E96-AE1A-1E8B69EC5679

Q33917702-AC738B66-5595-477F-9BB1-DB1DFD2B685B

Q33917702-F262C10F-A5EC-4D13-916D-38E390C09766

Q33917702-FFD2167D-A9D8-4EE8-882C-A8925C7CB932

P2860

Q33917702-01C0E824-F6AC-4B1A-92D1-99E7299690C7

Q33917702-03DE1A82-54A4-46EA-BB19-E913FF29DF2D

Q33917702-08138BF9-7ACF-4091-96EA-C7487D1107B2

Q33917702-1067BD93-76CC-4B4D-A6BC-EDE309E0C178

Q33917702-1228DC26-3F3C-45EF-86C4-3BC97D81CF86

Q33917702-1B681047-EBC0-4814-946C-BAAA02977EA6

Q33917702-1CCE86AE-46E9-454E-8DAE-FC220D771589

Q33917702-1CD91973-5771-4F3D-BBC4-00C0AB71EA85

Q33917702-1F795C6D-3067-445B-BB7C-DE9C4A0D092B

Q33917702-28E7C065-0663-4766-B10C-141BE4F222A6

P304

Q33917702-0020C494-8969-48E0-ACEA-08DAEF214848

P31

Q33917702-9A03C1A7-E031-4D1D-A0C1-61C4BECE5DCE

P356

Q33917702-99E47860-B11B-4417-851A-9FD3E520AC5F

P407

Q33917702-4CD93711-B494-456C-987F-8D2A817FC719

P433

Q33917702-49CF5C47-5F55-4A59-8ACF-A5B3CBBCA42E

P478

Q33917702-2AD94D3D-8770-41A5-9D9F-7DC4287DE7CC

P50

Q33917702-02ED58C0-4CEC-4722-A36F-5825A2B90F8D

Q33917702-190A1838-4E1D-4F44-9AAC-B48B1B587E4F

Q33917702-C9EA4492-F190-437F-B360-4EBF329712AF

Q33917702-D4E66C07-6419-4F34-A64D-5F9B4DB2D3C0

P577

Q33917702-84963919-3F67-4C94-86F4-8EF9E8C0C5FD

P5875

Q33917702-90D7DEFF-E0D5-42F1-BE33-AAE602090564

P698

Q33917702-CC68BF4F-9116-4697-96CF-E03AB41728B2

P921

Q33917702-158E3B65-10BE-4D45-9CB6-718B3FAD1D7C

Q33917702-375B287F-9F70-4691-B6FC-6AA33EFFFED5

Q33917702-8F34E208-3FFB-42EA-B21C-122EC733851E

P932

Q33917702-C15C90A3-BC32-4CDB-8F88-042615A95181

P356

J.NEUROIMAGE.2008.12.072

P1433

P1476

Categorical and correlational ...... euroimaging Initiative (ADNI).

@en

P2093

Adam S Fleisher

http://www.w3.org/2001/XMLSchema#string

Cole Reschke

http://www.w3.org/2001/XMLSchema#string

Dan Bandy

http://www.w3.org/2001/XMLSchema#string

Gene E Alexander

http://www.w3.org/2001/XMLSchema#string

Jessica B S Langbaum

http://www.w3.org/2001/XMLSchema#string

Norman L Foster

http://www.w3.org/2001/XMLSchema#string

Robert A Koeppe

http://www.w3.org/2001/XMLSchema#string

Wendy Lee

http://www.w3.org/2001/XMLSchema#string

William J Jagust

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia

Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.

Relationship between both IQ and Mini-Mental State Examination and the regional cerebral glucose metabolism in clinically diagnosed Alzheimer's disease: a PET study.

Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism.

Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET).

Current concepts in mild cognitive impairment.

Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease.

Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI).

P304

1107-1116

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.NEUROIMAGE.2008.12.072

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

45

http://www.w3.org/2001/XMLSchema#string

P50

Alzheimer's Disease Neuroimaging Initiative

Michael W. Weiner

P577

2009-01-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24260287

http://www.w3.org/2001/XMLSchema#string

P698

19349228

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

Alzheimer's Disease Neuroimaging Initiative

P932

2886795

http://www.w3.org/2001/XMLSchema#string